Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

Plenary paper

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein


The BCR-ABL oncogene is central in the pathogenesis of chronic myeloid leukemia (CML). Here, tandem mass spectrometry was used to demonstrate cell surface HLA-associated expression of the BCR-ABL peptide KQSSKALQR on class I-negative CML cells transfected with HLA-A’0301, and on primary CML cells from HLA-A3-positive patients. These patients mounted a cytotoxic T-lymphocyte response to KQSSKALQR that also killed autologous CML cells, and tetramer staining demonstrated the presence of circulating KQSSKALQR-specific T cells. The findings are the first demonstration that CML cells express HLA-associated leukemia-specific immunogenic peptides and provide a sound basis for immunization studies against BCR-ABL. (Blood. 2001;98:2887-2893)

© 2001 by The American Society of Hematology

Introduction

Chronic myeloid leukemia (CML) is a serious neoplastic disorder of the hematopoietic stem cell, characterized by an initial chronic phase of variable length, which commonly transforms to an incurable acute leukemia. Although an uncommon disease, CML has attracted a disproportionate amount of research attention, because the molecular genetics of the chronic phase are well understood and may represent a model for many other malignant conditions. The Philadelphia (Ph) translocation that typifies almost all cases juxtaposes the ABL gene on chromosome 9q34 to BCR on chromosome 22q11. Although the genomic breakpoints on both chromosomes 9 and 22 may vary from patient to patient over several kilobases, they occur only in introns.1 The resulting BCR-ABL messenger RNA (mRNA) transcript comprises a proximal BCR-derived portion ending with exon 2 or 3 (denoted by b2 or b3, respectively), fused to ABL exons 2 to 11 (denoted by a2).2 Almost all Ph-positive CML patients express either b3a2 or b2a2 fusion transcripts, depending on whether exon b3 is included. When translated, b2a2 and b3a2 mRNA each generate a 210-kDa BCR-ABL protein (p210), which is necessary and sufficient for leukemic transformation.3 The BCR-ABL junction in b3a2 mRNA disrupts a triplet codon, producing a novel lysine (K) at the junction in the b3a2 BCR-ABL protein product. A codon disruption also occurs at the b2a2 fusion junction (Asp altered to Glu), but in this case the novel amino acid may not be recognized as it is also present at the normal a1a2 junction.

Endogenous antigen is presented to the immune system by initial degradation to oligopeptides typically of 8 to 11 amino acids, which are assembled in the endoplasmic reticulum lumen into a stable complex with newly synthesized class I HLA α chain and β2 microglobulin. This complex is then exported to the cell surface, for recognition by cytotoxic T-lymphocytes (CTLs). Oligopeptides derived from the BCR-ABL junction are potential novel CML-specific antigens and may therefore elicit an immune response. Several class I HLA molecules have been reported to bind strongly to peptides spanning the BCR-ABL fusion junction.4-8 Bocchia et al4 identified BCR-ABL b3a2 junctional 9-mers that bound strongly to HLA-A3 and A11 (sequence KQSSKALQR) and B8 (sequence GFQSSKAL). These peptides also elicited specific class I-restricted CTL activity.5 HLA-A2 is capable of binding a different b3a2 fusion peptide that is able to elicit CTL responses in healthy donors and CML patients.6 These data suggest that certain BCR-ABL junctional peptides may preferentially bind to certain HLA alleles.

BCR-ABL junctional peptides can induce in vitro CTL activity or CD4+ cell proliferative responses in healthy subjects.5,6,8-16 Antigen presenting cells (APCs) loaded with BCR-ABL junctional 9-mers will elicit specific class I-restricted CTL activity from autologous fresh peripheral blood mononuclear cells (PBMCs).5,6 By using T-cell blasts pulsed with high concentrations of BCR-ABL peptide as APCs, we have recently reported that BCR-ABL-specific CTLs elicited from healthy subjects will kill CML cells in an HLA-restricted fashion,16 providing indirect evidence that CML cells may naturally express BCR-ABL junctional peptides. However, no evidence of BCR-ABL junctional peptides was seen among peptides eluted from HLA molecules on CML cells,17 although only HLA-A’0201 was studied. It is possible that the technique used in that work (high-performance liquid chromatography [HPLC]) may have been too insensitive to distinguish the low level of BCR-ABL peptides from among the “noise” of other extracted material. Furthermore, although tumor cell lysates have been shown to contain HLA-bound peptides that are recognized by antigen-specific CTLs,18-21 these experiments do not discriminate...
between intracellular and cell surface expressed HLA-peptide complexes. It is therefore not known whether CML cells can express BCR-ABL–derived and thus leukemia-specific peptides on the cell surface in the context of HLA. Direct proof of this would provide powerful scientific support for the development of immunization strategies against BCR-ABL.

Mass spectrometry with nanospray ionization (NSI/MS) is a sensitive technique available for the identification of small quantities of biological molecules. Skipper et al. used mass spectrometry to demonstrate that Melan A/MART 1 and gp100 HLA-A*0201–restricted epitopes can be eluted from surface class I HLA molecules on cultured melanoma cell lines. However, the application of mass spectrometry to study HLA-associated peptides on the surface of tumor cells has been limited. In adapting mass spectrometry to study primary tumor cells, a potential problem is that the identities of low-frequency tumor-specific peptides may be masked by those of other cell surface peptides, expressed on other HLA alleles. Furthermore, analysis is complicated by potential contamination by peptides/proteins from the intracellular compartments. To address this problem and using CML as a model, we have conceived a strategy that allows for the presentation and subsequent elution of peptides presented through a single HLA allele. In this instance, this is achieved by transfecting HLA-A*0301 into the HLA class I-negative CML cell line K562, which expresses b3a2 BCR-ABL mRNA.

In this study, we present for the first time evidence for surface HLA-A*0301–restricted b3a2 peptide expression, both on HLA-A*0301–transfected K562 cells and on CML cells from HLA-A3/B3a2 patients. Sequencing results obtained by using tandem mass spectrometry confirmed the presence of the HLA-A*0301–restricted peptide QKSSKALQR, with an identical signature on both transfected K562 and primary CML cells. We also show that these patients can mount a CTL response against the BCR-ABL junctional peptide expressed on their CML cells, and we report on the specificity of these CTLs. Furthermore, using tetramer staining, we demonstrate that HLA-A3–restricted peptide-specific T cells are detectable in the peripheral circulation of CML patients and that these T cells can be expanded specifically in vitro to provide increased levels of BCR-ABL–specific T cells.

Patients, materials, and methods

Patient population

Table 1 gives the clinical details of the 11 patients and controls included in the study, together with HLA assignments and BCR-ABL transcript type.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age (y)</th>
<th>Disease</th>
<th>Transcript type</th>
<th>HLA-A type</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>54</td>
<td>CML</td>
<td>b3a2</td>
<td>A2/A3</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>47</td>
<td>CML</td>
<td>b3a2</td>
<td>A3/A29</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>59</td>
<td>CML</td>
<td>b2a2</td>
<td>A2/A3</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>31</td>
<td>CML</td>
<td>b2a2</td>
<td>A1/A3</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>49</td>
<td>CML</td>
<td>b3a2</td>
<td>A1/A3</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>50</td>
<td>CML</td>
<td>b3a2</td>
<td>A2/A3</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>63</td>
<td>CML</td>
<td>b2a2</td>
<td>A2/A3</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>39</td>
<td>CML</td>
<td>b3a2</td>
<td>A2/A3</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>47</td>
<td>AML</td>
<td>N/A</td>
<td>A2/A3</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>22</td>
<td>Normal</td>
<td>N/A</td>
<td>A2/A3</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>41</td>
<td>Normal</td>
<td>N/A</td>
<td>A3/A3</td>
</tr>
</tbody>
</table>

CML, chronic myeloid leukemia; AML, acute myeloid leukemia; N/A, not applicable.

Six patients expressed the b3a2 transcript and 2 patients the b2a2 transcript. The controls were one BCR-ABL-negative acute myeloid leukemia (AML) patient and 2 healthy subjects. Five patients were positive for HLA-A*0301, and 2 patients were negative for HLA-A*0301 but were positive for b3a2. The remaining case was negative for HLA-A*0301 and expressed the b2a2 transcript. All samples for HLA-associated peptide analysis were obtained at leukapheresis carried out for routine clinical indications at original diagnosis. Leukapheresis was carried out by using a Cobe Spectra (Cobe Laboratories, Quedeley, Glos), programmed for maximal PBMC collection in accordance with the manufacturer’s instructions.

Cell lines and gene transfection

Transflectant cell lines expressing the single HLA allele HLA-A0301 were created from the major histocompatibility complex (MHC) class I-negative CML cell line K562 that is positive for the b3a2 BCR-ABL transcript. K562 cells were cultured in RPMI 1640 medium containing 10% fetal calf serum (FCS) (BioWhittaker, Wokingham, United Kingdom), penicillin (100 U/ml), streptomycin (100 μg/ml), gentamicin (50 μg/ml), HEPES buffer (10 mM), and L-glutamine (2 mM) (Gibco Life Technologies, Paisley, Scotland). Cells were maintained at 37°C in 5% CO2 in a humidified atmosphere. Briefly, the HLA-A*0301 allele was cloned into the expression vector pHJneo and transfected into the cells by electroporation. Following establishment of transfected cells in selective medium, expression of the transfected gene was verified by cell surface staining with the monoclonal antibody Gap-A3 specific for HLA-A*0301 followed by flow-activated cells sorter (FACS) analysis. The transfected cells were then cloned by limiting dilution to obtain cell lines expressing high levels of HLA-A*0301. Cells expressing higher levels of the transfected HLA allele were stained with the anti-HLA class I monoclonal antibody W6/32 and positively sorted for by FACS to further isolate transfectants with enhanced expression levels of HLA-A*0301. Transfected cell lines were maintained in RPMI 1640 selective medium containing G418 1 mg/ml (Gibco). Control lines consisting of vector alone were also created. The transflectant cell lines were checked for the continued expression of the transfected HLA allele by FACS analysis at regular intervals.

Synthetic peptide

The BCR-ABL fusion peptide sequence QKSSKALQR has been previously described as binding to HLA-A*0301. This peptide was made by using an ABI synthesizer with F-moc chemistry and purified by HPLC to more than 90% purity, then confirmed by mass spectrometry. It was dissolved in 50% dimethyl sulfoxide before use in the refolding of the HLA-A*0301 molecule for tetramer preparation (see below).

HLA-A*0301–associated peptide elution and purification

The acid elution technique was adapted from Storkus et al. The essential modifications were that prior to use, all plastic and glassware were treated in Sigmacote (Sigma, Poole, United Kingdom) to minimize peptide losses. Citrate phosphate buffer (0.131 M citric acid and 0.066 M sodium phosphate) was adjusted to pH 3.3 by using 10 M NaOH. A minimum of 10⁸ freshly leukapheresed CML cells or 5 × 10⁸ K562 transfecants/controls were washed in serum-free RPMI medium and centrifuged at 1500 rpm at 4°C for 5 minutes. Pelleted cells were resuspended in 20 mL citrate phosphate buffer for 5 minutes at room temperature and again centrifuged. The eluate-containing supernatant was collected and filtered through a 0.22-μm microfilter and stored at −80°C. Cellular integrity was assessed by using trypan blue, and the cells were found to be intact after citrate phosphate buffer elution.

Synthetic hepatitis B MHC class II-restricted peptide (TPPAYRPP-NAP121L115 900 fmol) was added to the cell eluate before biochemical purification and separation, as an internal recovery standard. Trichloroacetic acid (72% wt/vol, 2 mL) was added, and the sample was placed in an ultrasonic bath for 10 minutes, centrifuged for 10 minutes at 4°C at 15 000g, and followed by a further round of ultrasonication for 10 minutes. The supernatant was removed and applied to a cation exchange column (1 mL Econo S cartridge; BioRad, Hemel Hempstead, United Kingdom). The
column was washed with 0.1 M HCl (30 mL), and the bound peptides were eluted with 0.1 M NaOH (25 mL). The eluted peptide sample from the cation exchange column was brought to near-neutral pH with 2.8% vol/vol trifluoroacetic acid (TFA, 70 μL) and loaded via an injection loop onto an RP-HPLC precolumn (1 × 30 mm ODS; Jupiter, Phenomenex, Macclesfield, United Kingdom). The column was washed in solvent A (water containing 0.1% vol/vol TFA, 200 μL/min) to remove any residual buffer or cation exchange salts. The solvent flow was then redirected via a 6-port switching valve (Rhodyne 7030) with 20% solvent B (acetonitrile containing 5% vol/vol glacial acetic acid and 0.01% vol/vol TFA) and 80% solvent C (water containing 5% glacial acetic acid vol/vol and 0.01% TFA vol/vol) flowing through both the precolumn and the online analytical column used for peptide separation (1 × 150 mm ODS; Jupiter, Phenomenex). The columns were then subjected to an elution gradient of 20.80% to 90.10% solvent B:C (45 minutes, 20 μL/min), and 3 to 5 μL fractions were collected in silanized 1.1-mL tapered glass vials. To achieve low flow rates, a flow restrictor (microflow splitter; SGE, Milton Keynes, United Kingdom) was used with the HPLC pumps (ConstaMetric; Milton Roy, Wokingham, United Kingdom).

Mass spectrometric analysis and peptide identification

RP-HPLC fractions were analyzed by using an in-house constructed nano-electrospray ionization source interfaced to a quadrupole ion trap mass spectrometer (Finngan, Hemel Hempstead, United Kingdom). An Au/Pd-coated nano-electrospray tip (Nano-ES tip; Protana, Denmark) supported in a PTFE holder was attached to an adjustable platform, allowing movement along all 3 axes for the precise positioning of the tip near the heated capillary inlet of the mass spectrometer. The tip was gently broken against the heated capillary to initiate spraying and was maintained at a voltage of 1.1 kV by connection to the instrumental high-voltage power supply.

Mass spectrometric conditions were as follows: heated capillary 100°C, maximum injection time 400 ms, total microscans 3. The tube lens offset and heated capillary voltages were optimized for the doubly and triply protonated HLA-A*0301–associated peptide KQSSKALQR by running the synthetic peptide. The hepatitis B internal recovery standard peptide was isolated and analyzed to ensure that the level of recovery through the biochemical clean up was sufficient to allow mass spectrometric detection of natural peptides. Those peptides detected above the background noise were subjected to a zoom scan to ascertain their charge status. Ions found to be multiply charged in the mass range 300 to 800 Da were subjected to collisionally activated dissociation with an isolation width of 3 arbitrary mass units, a relative collision energy of 30%, and an automatic gain control at 3 arbitrary mass units.

Identification of HLA-A*0301–associated peptide KQSSKALQR

For each sample, the HPLC fractions found by NSI/MS to contain a triply charged ion corresponding to the HLA-A*0301–associated peptide KQSSKALQR were subjected to tandem mass spectrometry (MS/MS). Figure 1A shows the resulting MS/MS product ion spectrum for a control cell eluate to which synthetic KQSSKALQR was added at a concentration of 2.3 fmol/μL. The ions resulting from the fragmentation of the parent ion of KQSSKALQR had been predicted, using MS Product within the Protein Prospector database (University of California at San Francisco). The observed fragment ions (as labeled in Figure 1) matched with the database prediction. The presence of KQSSKALQR peptide was also confirmed by inputting the observed fragment ion masses into MS-Tag tool, with the finding that the observed fragment ion masses were unique to KQSSKALQR.

Figure 1C shows the MS/MS spectrum for an eluate from K562...
Mass spectrometric analysis was performed on 3 b3a2 BCR-ABL/HLA-A*0301-positive patients (cases 1-3) and one b3a2 BCR-ABL-positive/HLA-A*0301-negative patient (case 6). MS/MS product ion spectra characteristic of the KQSSKALQR peptide were found in eluates from the HLA-A*0301-positive cases expressing the b3a2 transcript. Figure 1B shows the MS/MS spectrum obtained from an eluate from the HLA-A*0301-positive primary CML cells (patient 1) in which the fragment ion pattern matches that observed for the synthetic peptide, confirming the presence of KQSSKALQR. In contrast, no evidence of the KQSSKALQR peptide was found above the mass spectrometric limit of detection in the HLA-A*0301-negative patient (case 6).

Tables of BCR-ABL-derived peptides able to bind to HLA-A*0301 were also predicted, using the computer algorithms BIMAS (http://www.bimas.dcrt.gov) and Syfpeithi (http://www.uni-tuebingen.de/kxi). These data allowed us to confirm that our defined peptide would also be selected as a potential binding candidate by the 2 commonly used peptide prediction algorithms.

**CTL directed against BCR-ABL junctional peptides**

Seven CML patients (5 HLA-A*0301 positive and 2 HLA-A*0301 negative) and 2 HLA-A*0301-positive healthy subjects were studied for evidence of CTL against BCR-ABL peptides as APCs. All 7 CML patients had well-controlled chronic phase CML at the time of sampling. The results are shown in Table 2. Effector CTLs were grown from all 7 HLA-A*0301-positive patients (5 CML patients and 2 healthy subjects), which were cytotoxic against autologous T-cell blasts expressing the HLA-A*0301–associated peptide KQSSKALQR. In all 7 HLA-A*0301-positive patients/controls, sufficient effectors were available to show that these CTLs were also cytotoxic against allogeneic HLA-A*0301-positive T-cell blasts pulsed with this peptide. Similarly, where sufficient CTL were available for study, these CTLs were also cytotoxic against unpulsed autologous and/or allogeneic HLA-A*0301-positive CML cells, although not against HLA-mismatched CML cells. Effector CTLs were not grown from the 2 HLA-A*0301-negative CML patients (cases 7 and 8 in Table 2).

**Table 2. Specificity of CTL generated with BCR-ABL peptide KQSSKALQR (% positive wells against target cells)**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Autologous CML cells</th>
<th>Matched CML cells</th>
<th>Mismatched CML cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA-A*0301 positive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>6</td>
<td>44</td>
<td>4</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>51</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>5</td>
<td>15</td>
<td>7</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>20</td>
<td>6</td>
</tr>
<tr>
<td>5</td>
<td>5</td>
<td>30</td>
<td>7</td>
</tr>
<tr>
<td>HLA-A*0301 negative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>1</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>8</td>
<td>5</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Healthy subjects</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>0</td>
<td>33</td>
<td>5</td>
</tr>
<tr>
<td>11</td>
<td>6</td>
<td>32</td>
<td>5</td>
</tr>
</tbody>
</table>

Data are expressed as the percentage of wells with 51Cr release > 3 SDs above the mean background 51Cr release. Percentages in bold were significantly different (P < .001) from their respective control (Fisher exact test). CTL, cytotoxic T lymphocyte; CML, chronic myeloid leukemia; —, not done because of insufficient effector cells; N/A, not applicable.
Detection and expansion of peptide-specific peripheral blood T cells with HLA-A*0301 tetramers

The results of the studies using the HLA-A*0301/KQSSKALQR peptide tetramer are given in Figure 2 and summarized in Table 3. Of the 6 patients studied, 2 patients (1 and 2) who were positive for b3a2 and HLA-A*0301 demonstrated circulating T cells reactive with the HLA-A*0301/KQSSKALQR peptide tetramer (Figure 2, panels 1A and 2A). Figure 2, panel 1C, demonstrates that stimulation with KQSSKALQR peptide (3 rounds) augmented tetramer-positive cells from 0.3% to 2.5%. The remaining b3a2 and HLA-A*0301-positive patient (patient 3), showed negligible levels of tetramer-positive cells (Figure 2, panel 3A). However, after 1 round of stimulation with KQSSKALQR, tetramer-positive cells were detectable (Figure 2, panel 3C). This finding illustrates that there is potential to expand leukemia-reactive T cells in vitro and that tetramer staining may be helpful in monitoring their expansion. This correlates with our finding that on in vitro stimulation with peptide it was possible to raise CTLs with a similar reactivity pattern in each of patients 1, 2, and 3 (Table 2). Expanded CTLs were not screened with tetramers in patients 2 and 5, as there were insufficient numbers of effector cells remaining after their use for specificity assays.

Patients 6 (b3a2-positive but HLA-A*0301-negative CML) and 9 (HLA-A*0301-negative AML) both showed no staining with the tetramer (Figure 2, panel 3A). These cases serve as negative controls for tetramer staining. As further controls, each patient was tested with tetramers of HLA-A2 with the HLA-A2-associated CMV peptide NLVPMVATV (central panels of Figure 2). Both patients who were HLA-A2 negative (patients 2 and 3) are negative for this tetramer (Figure 2, panels 2B and 3B), even though patient 2 is CMV positive. Similarly, patient 3 is HLA-A2 positive and CMV positive and shows tetramer-positive cells (Figure 2, panel 3B).

Discussion

The present study addresses 2 issues of importance to our understanding of immune mechanisms in cancer, namely the presentation of HLA-restricted tumor-specific peptides and the host T-cell response to such peptides. We focus on the CML-specific BCR-ABL protein. First, using the strategy of a class I-negative CML cell line transfected with a single HLA allele together with NSI/MS, we show that the HLA-A*0301–associated peptide KQSSKALQR is presented by transfected but not by nontransfected K562 cells. This finding demonstrates that a CML cell line can process the BCR-ABL fusion protein and can process and present peptides derived from the BCR-ABL junction on the cell surface in association with HLA class I antigen. The finding is in agreement with previous indirect evidence of HLA-associated BCR-ABL expression. We then extend this NSI/MS methodology to show that primary CML cells from b3a2/HLA-A*0301-positive patients also express KQSSKALQR on the CML cell surface. To our knowledge this represents the first direct evidence that a hematologic malignancy can express leukemia-specific peptides on the cell surface, in association with HLA class I antigens, which has until now remained unconfirmed. Second, we show that these patients can mount an in vitro CTL response against the BCR-ABL junctional peptide expressed on their CML cells and that these CTLs are capable of killing autologous CML cells. We also demonstrate by tetramer staining that KQSSKALQR-specific T cells are detectable in the peripheral circulation of these patients and that these T cells can be expanded specifically in vitro.

The demonstration that BCR-ABL junctional peptides can be eluted directly from CML cells is consistent with observations that appropriate synthetic 9-mer b3a2 peptides can bind HLA-A*0301. None of the 9-mer b3a2 peptides “shifted” by a single amino acid in either N- or C-terminal directions from KQSSKALQR were detected in the eluates. This finding is strong evidence that the defined HLA-binding peptide was not derived from nonspecific proteolysis but was processed and presented in association with class I HLA at the surface of CML cells. Neither of these shifted 9-mers were predicted to bind with high affinity to either HLA-A*0301 or to other class I HLA molecules expressed by the
patients. An eluate from a b3a2-positive HLA-A*0301-negative patient lacked the QKSSKALQR peptide, and this finding further supports the view that this peptide was derived from endogenously processed BCR-ABL protein presented in the HLA peptide binding groove in HLA-A*0301-positive CML cells.

Although we demonstrate that both BCR-ABL antigen presentation and CTL response are intact in CML, these mechanisms cannot operate optimally in vivo, otherwise the disease would never come to clinical attention. The PH-positive-initiating cell may not express BCR-ABL and may therefore escape immunologic detection. However, BCR-ABL transcripts have been detected in healthy subjects, using a sensitive reverse transcriptase-PCR assay, and both CTL and CD4+ proliferative responses against BCR-ABL can be elicited in healthy subjects. 5,6,8-10 CML may rarely spontaneously regress. 30-32 It is therefore interesting to speculate that certain CML clones may present suitably immunogenic peptides, which become targets for CTL. CML may be less common in HLA-A3-positive or B8-positive individuals, 33 suggesting that peptide immunogenicity may differ according to HLA type. It is plausible that the BCR-ABL rearrangement may be more common than the prevalence of CML, but that a T-cell response may control or eliminate a BCR-ABL-positive clone. Recent data suggest that a T-cell response against proteinase 3, a granule protein overexpressed in CML cells, may be important in clearing leukemic cells after therapy. 34 Thus, CML may come to clinical attention as a result of an immune tolerance or anergy to BCR-ABL, as well as the occurrence of the BCR-ABL rearrangement per se.

CTL precursors capable of being activated in vitro to kill autologous tumor cells have been described in malignant melanoma. 35 However, melanoma-associated antigens (MAGEs) are mostly unmutated self-antigens, such as MAGE1-3 or tyrosinase. 36 A completely novel tumor-specific antigen such as BCR-ABL would be less likely to induce tolerance or anergy than a normal self-antigen. However, there are a number of possible explanations for the failure of BCR-ABL to induce effective CTL in vivo in CML patients. These explanations include low T-cell receptor avidity or weak antigen expression or T-cell tolerance in patients with a massive leukemic burden. 17 Dendritic cells from CML patients are part of the leukemic clone, 28 and, hence, there is the potential for induction of T-cell tolerance to BCR-ABL via endogenous expression by thymic dendritic cells. Specific CD4+ T cells, which are thought to be essential for most CD8+ T-cell responses, 38 may be absent or anergic. It is notable that CD4+ T cells specific for b3a2 peptide could be detected in healthy donors but not in CML patients. 13 The requirement for specific CD4+ T cells in generating b3a2-specific CTL may be circumvented during in vitro CTL assays by the use of IL-2 and IL-7.

The potential promise of peptide vaccination for the therapy of malignant disease has yet to be realized. This may, in part, be due to difficulties in accurately defining tumor-specific peptides. The present strategy of using a single HLA-transfected cell line together with mass spectrometry demonstrates a novel approach for precise definition of HLA-associated peptides. This strategy may be widely applicable in many other malignant and nonmalignant disease states. The data support the view that immunization strategies against BCR-ABL may be helpful in boosting T-cell responses in CML. A recent preliminary report suggests that some CML patients may generate specific proliferative immune responses following vaccination with BCR-ABL junctional peptides, 37 although CTL responses were not observed in that study. The present findings give encouragement to further studies to define the optimal composition, route, and timing of administration of immunization with BCR-ABL junctional peptides.

In summary, the present data provide the first direct evidence that CML cells express surface BCR-ABL junctional peptides in association with HLA class I, and that antigen-specific T cells can target these peptides. CML can, therefore, be added to the list of examples of human tumors known to express a tumor-restricted peptide in the context of HLA.

References


